• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

Zydus Cadila gets US FDA nod for anti depressant

expressbpdJune 06, 2017

Tag: Zydus Cadila , FDA , anti depressant

Zydus Cadila has received the US health regulator’s nod to market Mirtazapine orally disintegrating tablets, an anti depressant, in the US market.

Zydus Cadila has received final approval from the US Food and Drug Administration (US FDA) to market the Mirtazapine orally disintegrating tablets USP in strengths 15mg, 30mg and 45mg, the company said in a BSE filing.

The company will manufacture the product at its facility in Baddi.

The Gujarat-based group has more than 115 approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

Previous:Protalix Wins FDA Approval as Multi-Product Facility

Next:Biocon appoints Pratima Rao as Mission Director of Biocon Foundation

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Zydus Cadila gets US FDA nod for anti depressant | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Mesnaum (FDA)

Mesnaum (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Deoxycyline (FDA)

Deoxycyline (FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Irinotecan (FDA)

Irinotecan (FDA)
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service